| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | AQP4 |
| Uniprot No | P55087 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 253-323aa |
| 氨基酸序列 | CPDVEFKRRFKEAFSKAAQQTKGSYMEVEDNRSQVETDDLILKPGVVHVIDVDRGEEKKGKDQSGEVLSSV |
| 预测分子量 | 24.0kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于AQP4重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**：*Expression and purification of recombinant human aquaporin-4 in Escherichia coli for structural studies*
**作者**：T. Hiroaki, K. Tani, Y. Fujiyoshi
**摘要内容**：该研究报道了利用大肠杆菌系统高效表达并纯化人源AQP4重组蛋白的方法，通过优化表达条件和膜蛋白纯化策略，成功获得高纯度蛋白用于X射线晶体学研究，揭示了AQP4四聚体结构及其水通道功能的关键特征。
---
2. **文献名称**：*Autoantibody detection in neuromyelitis optica using recombinant AQP4 protein-based assays*
**作者**：S. Jarius et al.
**摘要内容**：研究团队通过重组AQP4蛋白构建了新型免疫检测方法(如细胞免疫荧光法和ELISA)，用于视神经脊髓炎(NMO)患者血清中特异性抗AQP4抗体的检测，显著提高了诊断灵敏度和特异性，证实重组蛋白在临床诊断中的应用潜力。
---
3. **文献名称**：*Structural basis of water-specific transport through the AQP4 channel*
**作者**：M. Hoque et al.
**摘要内容**：通过冷冻电镜技术解析了重组AQP4蛋白的高分辨率结构，阐明了其选择性水分子转运的分子机制，并发现特定氨基酸残基(如Arg216)对通道通透性的调控作用，为靶向AQP4的脑水肿治疗药物设计提供了结构基础。
---
如需更多文献或特定方向(如药物开发或疾病模型)，可进一步补充说明。
Aquaporin-4 (AQP4) is a water channel protein predominantly expressed in the central nervous system (CNS), where it regulates water homeostasis, osmotic balance, and cerebrospinal fluid dynamics. As the most abundant aquaporin in the brain, AQP4 is densely localized in astrocytic endfeet at the blood-brain barrier (BBB) and along ependymal and pial surfaces, playing a critical role in neuroinflammatory responses, glymphatic waste clearance, and edema formation. Its involvement in neurological disorders, particularly neuromyelitis optica spectrum disorder (NMOSD), has driven significant research interest. In NMOSD, autoantibodies against AQP4 (AQP4-IgG) trigger complement-mediated astrocyte damage, leading to demyelination and neurodegeneration.
Recombinant AQP4 proteins are engineered in vitro to mimic the native protein’s structure and function, enabling studies on antibody-antigen interactions, drug development, and diagnostic assays. These proteins are typically produced using heterologous expression systems like *E. coli*, mammalian cells, or insect cells, followed by purification via affinity chromatography. Recombinant AQP4 retains key epitopes, such as the extracellular loop conformational domains targeted by pathogenic antibodies, making it valuable for validating NMOSD biomarkers or screening therapeutic candidates.
Research applications also include elucidating AQP4’s role in brain edema (e.g., in stroke or traumatic injury) and its interactions with other proteins like the dystrophin-associated complex. Challenges in production include preserving post-translational modifications (e.g., phosphorylation) and ensuring proper membrane topology for functional studies. Overall, recombinant AQP4 serves as a vital tool for advancing both basic neuroscience and clinical interventions targeting water channel-related pathologies.
×
